Abstract
Transdermal nicotine has been shown to relieve nicotine withdrawal and to double smoking cessation rates compared to placebo in clinical trials. A 21 or 22 mg/day dose provides a steady state serum nicotine that is less than obtained from smoking. Limited information is available about higher nicotine patch doses. To define better the optimal dosing of nicotine patch therapy, we undertook an open-label study to determine the safety and tolerability of 44 mg/day dose for smoking cessation in subjects smoking ≥ 20 cigarettes per day. Forty smokers received 44 mg/day of transdermal nicotine for 4 weeks followed by 4 weeks of 22 mg/day. Of the 40 subjects enrolled, 38 (95%) completed the 4 weeks of 44 mg patch therapy and 36 (90%) completed the entire 8 weeks of patch therapy. Non-smokers at week 4 had a mean serum nicotine level of 23.4±11.7 ng/ml and cotinine of 152.2±87.3 ng/ml. Percent replacement was calculated by dividing the steady state level at week 4 by the baseline level while the subjects were smoking their usual number of cigarettes. Percent nicotine replacement for non-smokers at week 4 (while on 44 mg nicotine patch) averaged 158%±108.4, and for cotinine was 112.0±73.8. For nicotine, 33% of non-smokers at week 4 had ≤ 100% nicotine replacement and for cotinine 63% ≤ 100% replacement. Biochemically confirmed point prevalence smoking cessation rates were 65% and 55% at weeks 4 and 8 of patch therapy, respectively, and self-reported smoking cessation at 3 months was 50%. The most common effect was skin irritation at the patch site. A single subject was admitted for myocardial infarction following step-down from 44 to 22 mg of replacement nicotine. The subject was not smoking and the adverse event was deemed to be not related to the patch therapy. Sleep complaints were reported in 33% of subjects during the 44 mg phase. Other complaints were infrequent. We conclude that 44 mg per 24-h nicotine patch therapy in heavy smokers is safe, tolerable, and without significant adverse events.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abelin T, Buehler A, Muller P (1989) Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet 1: 7–10
Bannon YB, Corish J, Corrigan OI, Devane JG, Kavanaugh M, Mulligan S (1989) Transdermal delivdery of nicotine in normal human volunteers. Eur. J Clin Pharmacol 37:285–290
Benowitz NL (1986) The human pharmacology of nicotine. Res Add Alcohol Drug Probl 9:1–52
Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q (1993): Nicotine effects on eicosanoid and hemostatic function: Comparison of transdermal nicotine and cigarette smoking. J. Am Coll Cardio 22:1159–1167
Buchkremer G, Minneker E, Block M (1991) Smoking cessation treatment combining transdermal nicotine substitution with behavior therapy. Pharmacopsychiatry 24:96–102
Daughton DM, Heatley SA, Prendergast JJ (1991) Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. Arch Int Med 151:749–752
Fagerstrom KO (1978) Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 3:235–241
Fiore MC, Jorenby DE, Baker TB (1992) Tobacco dependence and the nicotine patch: clinical guidelines for effective use. JAMA 268[19]:2687–2694
Fiore MC, Smith SS, Joremby DE, Baker TB (1994) The effectiveness of nicotine patch for smoking cessation, a meta-analysis. JAMA 271:1940–1947
Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED (1993) Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 33:23–29
Hughes JR, Hatsukami D (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43:289–294
Hurt RD, Morse RN, Swenson WN (1980) Diagnosis of alcoholism with a self administered alcoholism screening test: Results with 1,002 consecutive patients receiving general medical examinations. Mayo Clin Proc 55:365–370
Hurt RD, Lauger GG, Offord KP (1990) Nicotine therapy with use of a transdermal nicotine patch: a randomized double-blind placebo-controlled trial. Mayo Clin Proc 65:1529–1537
Hurt RD, Dale LC, Offord KP, Lauger GG, Baskin LB, Lawson GM, Jiang N, Hauri PJ (1993) Serum nicotine and cotinine levels during nicotine-patch therapy. Clin Pharmacol Ther 54:98–106
Hurt RD, Dale LC, Fredrickson PA (1994) Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up one-year outcome and percentage nicotine replacement. JAMA 1994; 271:595–600
Kyerematen GA, Morgan ML, Chattopadhyay B, deBethizy JD, Vesell ES (1990) Disposition of nicotine and eight metabolites in smokers and nonsmokers. Clin Pharmacol Ther 48:641–651
Orleans CT, Resch N, Noll E, Keintz MK, Rimer BK, Brown TV, Snedden TM (1994) Use of transdermal nicotine in a state-level prescription plan for the elderly. JAMA 271:601–607
Rose JE, Lebin ED, Behm FM (1990) Transdermal nicotine facilitates smoking cessation. Clin Pharmacol Ther 47:323–330
Sachs DPL, Säwe U, Leischow SJ (1993) Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting without intensive group counseling. Arch Int Med 153:1881–1890
Tonnesen P, Norregaard J, Simonsen K (1991) A double-blind trial for a 16-hr transdermal nicotine patch in smoking cessation. N Engl J Med 325:311–315
Transdermal Nicotine Study Group (1991) Transdermal nicotine for smoking cessation. JAMA 226:3133–3138
Wall Street Journal (1992) Friday, June 19
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fredrickson, P.A., Lee, G.M., Wingender, L. et al. High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology 122, 215–222 (1995). https://doi.org/10.1007/BF02246542
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02246542